Adalimumab for the treatment of psoriasis in real life: A retrospective cohort of 119 patients at a single Spanish centre

British Journal of Dermatology

Volumn 169, Issue 5, 2013, Pages 1141-1147

  Lopez Ferrer A ^a   Vilarrasa, E ^a   Gich, I J ^a   Puig, L ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETRETIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUBERCULOSTATIC AGENT;

ABSCESS; ADULT; AGED; ALCOHOLISM; ARTICLE; BRONCHITIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FURUNCULOSIS; GASTROENTERITIS; HEART INFARCTION; HERPES SIMPLEX; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; LATENT TUBERCULOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MILIARY TUBERCULOSIS; MUSCLE CRAMP; NONALCOHOLIC FATTY LIVER; OBESITY; OPEN STUDY; PARONYCHIA; PATIENT MONITORING; PATIENT REFERRAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATITIS; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SCABIES; SPAIN; SURVIVAL; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; VASCULITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887091263     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12543     Document Type: Article

References (29)

1. Gordon KB, Langley RG, Leonardi C, et al,. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
2. Saurat JH, Stingl G, Dubertret L, et al,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
3. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
4. Thaçi D, Ortonne JP, Chimenti S, et al,. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-11.
5. Asahina A, Nakagawa H, Etoh T, Ohtsuki M,. Adalimumab in Japanese patients with moderate to severe chronic plaques psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
6. Menter A, Gordon KB, Leonardi CL, et al,. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-56.
7. Schmitt J, Zhang Z, Wozel G, et al,. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26.
8. Lucka TC, Pathirana D, Sammain A, et al,. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012; 26: 1331-44.
9. Gordon K, Papp K, Poulin Y, et al,. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-51.
10. Garcia-Doval I, Carretero G, Vanaclocha F, et al,. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible versus eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-70.
11. Leonardi C, Sobell JM, Crowley JJ, et al,. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol 2012; 167: 658-67.
12. Philipp S, Wilsmann-Theis D, Weyergraf A, et al,. Combination of adalimumab with traditional systemic antipsoriatic drugs-a report of 39 cases. J Dtsch Dermatol Ges 2012; 10: 821-37.
13. Lecluse LL, De Groot M, Bos JD, Spuls PI,. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 2009; 161: 948-51.
14. Van Lümig PP, Lecluse LL, Driessen RJ, et al,. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010; 163: 838-46.
15. Bissonnette R, Bolduc C, Poulin Y, et al,. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 2010; 63: 228-34.
16. Strober BE, Poulin Y, Kerdel FA, et al,. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 2011; 64: 671-81.
17. Puig L,. Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios. Br J Dermatol 2013; 168: 674-6.
18. Warren RB, Brown BC, Lavery D, Griffiths CE,. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2010; 163: 859-62.
19. Ryan C, Kirby B, Collins P, Rogers S,. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol 2009; 34: 784-8.
20. Papoutsaki M, Chimenti MS, Costanzo A, et al,. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-75.
21. van Lümig PP, van de Kerkhof PC, Boezeman JB, et al,. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol 2013; 27: 593-600.
22. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D,. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre. J Eur Acad Dermatol Venereol 2012; 26: 1298-303.
23. Reich K, Burden AD, Eaton JN, Hawkins NS,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-88.
24. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
25. Brunasso AM, Puntoni M, Massone C,. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol 2012; 166: 447-9.
26. Lecluse LL, Driessen RJ, Spuls PI, et al,. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-32.
27. Mahil SK, Arkir Z, Richards G, et al,. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol 2013; 169: 306-13.
28. Sánchez-Moya AI, Dauden E,. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol 2011; 25: 730-3.
29. Sánchez-Moya AI, García-Doval I, Carretero G, et al,. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/jdv.12011. [Epub ahead of print].